Neurotez, Inc. Reports Development of a Method to Isotype the Human TOMM40 Variable-Length Polymorphism

Published: Mar 22, 2011

BRIDGEWATER, N.J.--(BUSINESS WIRE)--The new Neurotez method will allow for an elegant and rapid way to screen a large number of patient-derived samples and measure the degree of confidence in predicting a subject's risk for getting Alzheimer's disease, based on her/his TOMM40/APOE haplotype. TOMM40 has been implicated as a potential biomarker for those at risk for developing Alzheimer's disease, based on work by Allen Roses' team at Duke University's Deane Drug Discovery Institute.

Back to news